FitRX, LLC
Has FitRX, LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued FitRX, LLC 3 warning letters naming semaglutide and tirzepatide, the latest dated Jun 8, 2026, with the FDA subject line “False & Misleading Claims/Misbranded (Telehealth).”
FDA records in this index name FitRX, LLC from Sep 9, 2025 to Jun 8, 2026.
- Names in FDA records
- FitRX, LLC dba AM RX; FitRX, LLC dba FitRx; FitRX, LLC dba Zealthy
- Websites the letters name
- fitrxapp.com, getamrx.com, getzealthy.com (see how each letter refers to them)
- Type named in FDA records
- Telehealth
- FDA warning letters
- 3
- Drug recall reports
- 0
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Jun 8, 2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Jun 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Jun 8, 2026: … your website offers compounded drug products, including semaglutide and tirzepatide products. 1 As described below, … website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) … or operations. Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. … Full letter
- Feb 20, 2026: … your website offers compounded drug products, including semaglutide and tirzepatide drug products. 1 As described … website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) … is false or misleading in any particular. The compounded semaglutide and tirzepatide products displayed on your … Full letter
- Sep 9, 2025: … website offers various compounded drug products, including semaglutide . As described below, your claims concerning compounded semaglutide products are false or misleading under sections … any particular. The following claims concerning compounded semaglutide products appear on your website: • “Is … Full letter
Websites named in the letters
Each letter below is addressed to the firm FDA names in it, not to a website. The sentence quoted is the letter’s own reference to the site, copied from the letter on fda.gov.
- getamrx.com: FDA’s warning letter of Jun 8, 2026 is addressed to FitRX, LLC dba AM RX. It refers to the site in these words: “FDA Review Violations were identified and documented during a review of AM RX’s website, https://getamrx.com, FDA Establishment Identifier (FEI) 3044021238, in March 2026.” Full letter
- fitrxapp.com: FDA’s warning letter of Feb 20, 2026 is addressed to FitRX, LLC dba FitRx. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.fitrxapp.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” Full letter
- getzealthy.com: FDA’s warning letter of Sep 9, 2025 is addressed to FitRX, LLC dba Zealthy. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.getzealthy.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” Full letter
Drug recalls
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Jun 8, 2026
- FDA warning letter, Feb 20, 2026
- FDA warning letter, Sep 9, 2025
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.